* CYTHERIS *
1999 - IDF
Issy-les-Moulineaux
(near Paris)
www.cytheris.com Discovery, Immunology
Key words: Immune modulation, Cancer, HIV, HCV, Recombinant interleukin
Mission: to discover and develop new therapies for immune modulation, by reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT)
Clients: Prescribers
info@cytheris.com
Age: 11 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.-CEO: Morre (Michel) [founder, born 1946, Vet.D., ex-Sanofi-Aventis, Pierre Fabre, M.I.T.]
Sc.Dir.-CSO:
Fin.Dir.-CFO: Vannier (Bertrand)
BusDev: Keatinge (Richard W.) [ex-BioAlliance Pharma]
Financers (Hist.): Bioam, GestionT2C2/Bio, CDP Capital Technology Ventures, AXA P.E., Crédit Agricole P.E., CDC Innovation, Forbion (registered capital 2006 = 52.5 M€) | Turnover (M€) : 0.09 (2007), 0.14 (2006)
Total funding (M€) : 31.3
Last funding (M€) : 24.3
Focus : Cancers
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .07 | Patent : notice of Allowance for U.S. Patent covering the pharmaceutical composition of Recombinant Human Interleukin-7 (CYT107) | LEGAL | [10 years] |
| 2009 .06 | Research : publication in Nature Medicine showing that combination of Interleukin-7 with viral vaccine boosts immunity to tumors | R&D | [10 years] |
| 2009 .03 | Clinical trial (phase IIa) for recombinant IL-7 (completed), which induces a dramatic and prolonged CD4 and CD8 T cell expansion, sustained for 48 weeks in HIV patients | CLIN | [10 years] |
| 2008 .07 | Financing (no interest loan) : 1.5 M€, by OSEO, to support its ongoing clinical development program in hepatitis C (HCV) | DEBT | [9 years] |
| 2007 .02 | Clinical trial (phase I) for recombinant IL-7 (beginning) | CLIN | [8 years] |
| 2006 .10 | 2nd round-financing : 24.3 M€, by CDC Innovation with ABN AMRO Capital Life Sciences (today, Forbion) and previous shareholders | RFINB | [7 years] |
| 2005 .05 | Licensing-in of a new immuno-modulating agent for HIV from New York University | LICIN | [6 years] |
| 2003 .00 | Set-up of US subsidiary in Rockville, Maryland | ORGC | [3 years] |
| 2002 .07 | 1st round-financing : 7.0 M€, by Bioam with two Canadian funds, GestionT2C2/Bio and CDP Capital Technology Ventures, plus AXA P.E. and Crédit Agricole P.E. | RFINA | [3 years] |
| 1999 .04 | Licensing-in of Interleukin-7 (IL-7) from Sanofi-Aventis | LICIN | [0 year] |
| 1999 .01 | Company founded by Michel Morre (CEO), as Biotech Inflection Point | ORGF | [0 year] | Actualisation / Updating: 07-Sept-2009 |
|
